Click Here for 5% Off Your First Aladdin Purchase!

Cerdulatinib - 98%, high purity , Tyrosine-protein kinase TYK2 inhibitor, CAS No.1198300-79-6, Tyrosine-protein kinase TYK2 inhibitor

  • Moligand™
  • ≥98%
Item Number
C413025
Grouped product items
SKUSizeAvailabilityPrice Qty
C413025-10mg
10mg
In stock
$155.90
C413025-25mg
25mg
In stock
$351.90
C413025-50mg
50mg
In stock
$521.90
C413025-100mg
100mg
In stock
$808.90
C413025-200mg
200mg
In stock
$1,200.90

Basic Description

SynonymsCerdulatinib|1198300-79-6|Cerdulatinib (PRT062070)|Cerdulatinib [INN]|PRT062070|UNII-D1LXQ45S1O|D1LXQ45S1O|4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide|PRT-062070|4-(Cyclopropylamino)-2-((4-(4-(ethanesulfonyl)p
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsCerdulatinib (PRT062070, PRT2070) is a potent and selective inhibitor of Tyk2 with IC50 of 0.5 nM. Cerdulatinib is also a dual inhibitor of JAK and SYK with IC50 of 12 nM, 6 nM, 8 nM and 32 nM for JAK1, JAK2, JAK3 and SYK, respectively.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionTyrosine-protein kinase TYK2 inhibitor

Associated Targets

CSF1R Tclin Macrophage colony-stimulating factor 1 receptor 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

STK4 Tchem Serine/threonine-protein kinase 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TYK2 Tclin Non-receptor tyrosine-protein kinase TYK2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

JAK3 Tclin Tyrosine-protein kinase JAK3 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SYK Tclin Tyrosine-protein kinase SYK 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

JAK1 Tclin Tyrosine-protein kinase JAK1 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NUAK1 Tchem NUAK family SNF1-like kinase 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

JAK2 Tclin Tyrosine-protein kinase JAK2 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAP3K9 Tchem Mitogen-activated protein kinase kinase kinase 9 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488201014
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488201014
IUPAC Name 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
INCHI InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
InChi Key BGLPECHZZQDNCD-UHFFFAOYSA-N
Canonical SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
Isomeric SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
PubChem CID 44595079
Molecular Weight 445.54

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
D2328201Certificate of AnalysisMar 24, 2023 C413025
D2328204Certificate of AnalysisMar 24, 2023 C413025
D2328206Certificate of AnalysisMar 24, 2023 C413025
D2328211Certificate of AnalysisMar 24, 2023 C413025
D2328212Certificate of AnalysisMar 24, 2023 C413025
D2328217Certificate of AnalysisMar 24, 2023 C413025
D2328218Certificate of AnalysisMar 24, 2023 C413025
E2304142Certificate of AnalysisMar 24, 2023 C413025
E2304147Certificate of AnalysisMar 24, 2023 C413025
E2304162Certificate of AnalysisMar 24, 2023 C413025

Related Documents

References

1. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U.  (2014)  The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer..  J Pharmacol Exp Ther,  351  (3): (538-48).  [PMID:25253883]

Solution Calculators